The firm is now inking revenue-generating contracts with other biotech companies for its drug response prediction and gene expression analysis capabilities.

If approved by the EC, Tagrisso will be the first targeted therapy for European patients with unresectable EGFR-mutated cancer.

NEW YORK – The European Commission (EC) on Monday granted marketing authorization to AbbVie's Elahere (mirvetuximab soravtansine) as a new therapy option for previously treated patients with folate ...

Following this update, the company's stock price dropped more than 30 percent from market close Friday to $23.79 per share Monday morning.

Eight NHS cancer centers will examine tumors from patients with exceptional survival times, focusing on three aggressive cancer types.

NEW YORK – AstraZeneca has selected an autologous T-regulator (Treg) cell therapy candidate from Quell Therapeutics' pipeline to advance into preclinical and clinical trials in type 1 diabetes, ...

In the AUGMENT-101 trial, 21 percent of patients achieved complete remission plus complete remission with partial hematological recovery on the drug.

Researchers worked with two labs to identify 16 consensus lower-risk pathogenic variants and are pushing for greater ...

Patients with MSI-high/dMMR advanced colorectal cancers had a 79 percent lower risk of disease progression or death on Opdivo-Yervoy compared to chemo.

January, come a year after the drugmaker slashed 7 percent of the workforce at Kite Pharma, its cell therapy business.

The US Food and Drug Administration approved Augtyro in 2023 for the treatment of ROS1-positive advanced NSCLC. Earlier this year, the FDA also approved the drug for adult and pediatric patients 12 ...